Limelight Networks and Tencent Cloud to Provide Seamless Global Content Delivery
18.1.2018 15:30:00 EET | Business Wire | Press release
Limelight Networks, Inc. (Nasdaq: LLNW), a global leader in digital content delivery, and Tencent Cloud announced an agreement that expands access to each company’s services. Under terms of the agreement, Limelight will offer its customers Content Delivery Network (CDN) services in China through Tencent Cloud. Tencent Cloud will offer CDN services from Limelight to Tencent Cloud customers in North America and other global markets.
Tencent Cloud is a secure, reliable and high-performance public cloud service provider that integrates Tencent’s infrastructure-building capabilities with the advantages of a massive-user platform and ecosystem.
“Partnering with Limelight is one example of how Tencent Cloud is expanding its services and capabilities to meet the rapidly growing global demand for high-performance cloud services,” said Carlos Morell, Vice President, Tencent Cloud International. “For global companies that want to operate in China as well as Chinese companies that want to go global, Tencent Cloud makes it easy to enable and enhance operations and extend existing IT infrastructure to a more powerful, reliable and intelligent platform.”
Tencent Cloud provides global access and a rich array of services to organizations which need advanced infrastructure and a resilient environment, such as gaming, video, live broadcast, and finance companies.
Limelight has a global footprint and its unique combination of private infrastructure, advanced software, and expert services surpasses other CDNs. Together, Limelight and Tencent offer a seamless solution to global customers who want to deliver content around the world.
"Limelight is one of the largest global content delivery networks in the world, and this agreement will further extend our reach into China. The quality, bandwidth, reach and security of our global private network delivers high-quality digital experiences that audiences demand worldwide,” said Ersin Galioglu, Vice President of Strategic Initiatives at Limelight Networks. “China is experiencing digital adoption at an accelerating pace, and there’s a unique opportunity for global businesses to access the Chinese market and for Chinese businesses to have access to global consumers. Together, Limelight and Tencent will work to address this opportunity. This collaboration brings unique expertise and capabilities to businesses worldwide that want and need to deliver digital content from anywhere, to anyone, in milliseconds.”
About Tencent
Tencent uses technology to enrich the lives of
Internet users. Tencent’s social products, Weixin and QQ, link its users
to a rich, digital content catalogue including games, video, music and
books. Its proprietary targeting technology helps advertisers reach out
to hundreds of millions of consumers in China. Tencent’s infrastructure
services, including payment, security, cloud and artificial
intelligence, create differentiated offerings and support its partners’
business growth. Tencent invests heavily in people and innovation,
enabling the company to evolve with the Internet.
Tencent was founded in Shenzhen, China in 1998. Shares of Tencent (00700.hk) are traded on the Main Board of the Stock Exchange of Hong Kong.
About Limelight
Limelight Networks, a global leader in
digital content delivery, empowers customers to better engage online
audiences by enabling them to securely manage and globally deliver
digital content, on any device. The company’s Limelight Orchestrate
Platform includes a global infrastructure with a fully-integrated suite
of capabilities and services to help you address all your content
delivery needs. The Orchestrate Platform solves your most important
content delivery challenges so you can deliver the next great digital
experience anywhere. For more information, please visit www.limelight.com
and follow us on Twitter,
Facebook
and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180118005684/en/
Contact information
SHIFT Communications
Lori Niquette, 617-779-1800
Limelight@shiftcomm.com
or
Investor
Inquiries: ir@limelight.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom